Lenvervimab
Lenvervimab is a monoclonal antibody designed for the treatment of COVID-19. It was developed by Celltrion, a South Korean biopharmaceutical company. Lenvervimab is also known by its developmental code name, CT-P59.
Mechanism of Action[edit | edit source]
Lenvervimab works by binding to the spike protein of the SARS-CoV-2 virus, preventing the virus from entering human cells. This mechanism of action is similar to other monoclonal antibodies used in the treatment of COVID-19.
Clinical Trials[edit | edit source]
Lenvervimab has undergone Phase I, Phase II, and Phase III clinical trials. The results from these trials have shown that Lenvervimab is effective in reducing the severity of COVID-19 symptoms and the duration of the disease.
Approval[edit | edit source]
In February 2022, Lenvervimab was granted conditional approval by the Ministry of Food and Drug Safety (MFDS) in South Korea for the treatment of COVID-19.
Side Effects[edit | edit source]
As with all medications, Lenvervimab can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, and diarrhea.
See Also[edit | edit source]
Lenvervimab Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD